Roche’s Vabysmo demonstrates sustained two-year results in a difficult-to-treat form of neovascular age-related macular degeneration (nAMD)
Sustained two-year efficacy data for difficult-to-treat nAMD signals strong clinical validation.
What changed
Sustained two-year efficacy data for difficult-to-treat nAMD signals strong clinical validation.
Why it matters
Sustained two-year efficacy data for difficult-to-treat nAMD signals strong clinical validation. — impact context not separately stored; see What changed.
← Dashboard
Aug 28, 2026 08:01 AM ET